Pentablock Copolymer Dexamethasone Nanoformulations Elevate MYOC: in Vitro Liberation, Activity and Safety in Human Trabecular Meshwork Cells

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2017 Aug 1

PMID 28756742

Citations 5

Authors

Vibhuti Agrahari

Guorong Li

Vivek Agrahari

Iris Navarro

Kristin Perkumas

Abhirup Mandal

W Daniel Stamer

Ashim K Mitra

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of this study is to examine the elevation of MYOC in long-term treatment of human trabecular meshwork (HTM) cells using dexamethasone (DEX) encapsulated pentablock (PB) copolymer-based nanoparticles (NPs) (DEX-PB-NPs).

Materials & Methods: PB copolymers and DEX-PB-NPs were synthesized and characterized using nuclear magnetic resonance, gel permeation chromatography, and X-ray diffraction analyses. MYOC levels secreted from HTM cells were measured by western blot (WB) analysis.

Results: DEX-PB-NPs were formulated in the size range of 109 ± 3.77 nm (n = 3). A long term DEX release from the NPs was observed over three months. Cell viability and cytotoxicity were not affected up to 12 weeks of treatment with PB-copolymer or DEX-PB-NPs. WB data from five HTM cell strains showed that MYOC levels increased by 5.2 ± 1.3, 7.4 ± 4.3, and 2.8 ± 1.1-fold in the presence of DEX-PB-NPs compared with 9.2 ± 3.8, 2.2 ± 0.5, and 1.5 ± 0.3-fold at 4, 8 and 12 weeks in control-DEX treatment group, respectively (n = 5). Based on the decline in MYOC levels after withdrawal of DEX from control wells, DEX-PB-NPs released the DEX for at least 10 weeks.

Conclusion: The treatment of HTM cells using DEX-PB-NPs were analyzed in this study. The in vitro cell-based system developed here is a valuable tool for determining the safety and effects of steroids released from polymeric NPs.

Citing Articles

Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.

Li G, Lee C, Read A, Wang K, Ha J, Kuhn M Elife. 2021; 10.

PMID: 33783352 PMC: 8009676. DOI: 10.7554/eLife.60831.

The role of EP receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1.

Bertrand J, Woodward D, Sherwood J, Wang J, Overby D Br J Ophthalmol. 2020; 105(11):1610-1616.

PMID: 33239414 PMC: 8875279. DOI: 10.1136/bjophthalmol-2020-317762.

In vivo measurement of trabecular meshwork stiffness in a corticosteroid-induced ocular hypertensive mouse model.

Li G, Lee C, Agrahari V, Wang K, Navarro I, Sherwood J Proc Natl Acad Sci U S A. 2019; 116(5):1714-1722.

PMID: 30651311 PMC: 6358695. DOI: 10.1073/pnas.1814889116.

Physiological function of myocilin and its role in the pathogenesis of glaucoma in the trabecular meshwork (Review).

Wang H, Li M, Zhang Z, Xue H, Chen X, Ji Y Int J Mol Med. 2018; 43(2):671-681.

PMID: 30483726 PMC: 6317685. DOI: 10.3892/ijmm.2018.3992.

The relationship between outflow resistance and trabecular meshwork stiffness in mice.

Wang K, Li G, Read A, Navarro I, Mitra A, Stamer W Sci Rep. 2018; 8(1):5848.

PMID: 29643342 PMC: 5895808. DOI: 10.1038/s41598-018-24165-w.

References

Boddu S, Jwala J, Vaishya R, Earla R, Karla P, Pal D . Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J Ocul Pharmacol Ther. 2010; 26(1):37-48. PMC: 3096543. DOI: 10.1089/jop.2009.0074. View

Sudhalkar A, Chhablani J, Vasavada A, Bhojwani D, Vasavada V, Vasavada S . Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series. Eye (Lond). 2016; 30(12):1549-1557. PMC: 5177766. DOI: 10.1038/eye.2016.205. View

Vaishya R, Gokulgandhi M, Patel S, Minocha M, Mitra A . Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. AAPS PharmSciTech. 2014; 15(5):1238-51. PMC: 4179657. DOI: 10.1208/s12249-014-0100-4. View

Haller J, Bandello F, Belfort Jr R, Blumenkranz M, Gillies M, Heier J . Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011; 118(12):2453-60. DOI: 10.1016/j.ophtha.2011.05.014. View

Narayanan R, Kuppermann B . Corticosteroids and Anti-Complement Therapy in Retinal Diseases. Handb Exp Pharmacol. 2016; 242:309-320. DOI: 10.1007/164_2016_22. View

Yang X, Trinh H, Agrahari V, Sheng Y, Pal D, Mitra A . Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. AAPS PharmSciTech. 2015; 17(2):294-306. PMC: 4984892. DOI: 10.1208/s12249-015-0354-5. View

Agrahari V, Agrahari V, Mandal A, Pal D, Mitra A . How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv. 2016; 14(10):1145-1162. DOI: 10.1080/17425247.2017.1272569. View

Patel S, Vaishya R, Patel A, Agrahari V, Pal D, Mitra A . Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul. 2016; 33(2):103-13. PMC: 5026050. DOI: 10.3109/02652048.2015.1134685. View

Gerecke C, Edlich A, Giulbudagian M, Schumacher F, Zhang N, Said A . Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes. Nanotoxicology. 2017; 11(2):267-277. DOI: 10.1080/17435390.2017.1292371. View

10.

Stamer W, Hoffman E, Kurali E, Krauss A . Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013; 54(3):2100-7. PMC: 4601886. DOI: 10.1167/iovs.12-11298. View

11.

Stamer D, Roberts B, Epstein D, Allingham R . Isolation of primary open-angle glaucomatous trabecular meshwork cells from whole eye tissue. Curr Eye Res. 2000; 20(5):347-50. View

12.

Chuang T, Pearce W, Khorram O . miR-29c induction contributes to downregulation of vascular extracellular matrix proteins by glucocorticoids. Am J Physiol Cell Physiol. 2015; 309(2):C117-25. PMC: 4504943. DOI: 10.1152/ajpcell.00254.2014. View

13.

Wu X, Li S, Coumes F, Darcos V, Lai Kee Him J, Bron P . Modeling and self-assembly behavior of PEG-PLA-PEG triblock copolymers in aqueous solution. Nanoscale. 2013; 5(19):9010-7. DOI: 10.1039/c3nr02899b. View

14.

Loftsson T, Hreinsdottir D, Stefansson E . Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol. 2007; 59(5):629-35. DOI: 10.1211/jpp.59.5.0002. View

15.

Coassin M, Iovieno A, Soldani A, Cavuto S, Cimino L, Sartori A . Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome. J Cataract Refract Surg. 2016; 42(8):1119-25. DOI: 10.1016/j.jcrs.2016.04.031. View

16.

Clark A, Wordinger R . The role of steroids in outflow resistance. Exp Eye Res. 2008; 88(4):752-9. DOI: 10.1016/j.exer.2008.10.004. View

17.

Schwartz S, Scott I, Stewart M, Flynn Jr H . Update on corticosteroids for diabetic macular edema. Clin Ophthalmol. 2016; 10:1723-30. PMC: 5019446. DOI: 10.2147/OPTH.S115546. View

18.

Agrahari V, Agrahari V, Hung W, Christenson L, Mitra A . Composite Nanoformulation Therapeutics for Long-Term Ocular Delivery of Macromolecules. Mol Pharm. 2016; 13(9):2912-22. DOI: 10.1021/acs.molpharmaceut.5b00828. View

19.

Bian F, Pelegrino F, Henriksson J, Pflugfelder S, Volpe E, Li D . Differential Effects of Dexamethasone and Doxycycline on Inflammation and MMP Production in Murine Alkali-Burned Corneas Associated with Dry Eye. Ocul Surf. 2016; 14(2):242-54. PMC: 4842328. DOI: 10.1016/j.jtos.2015.11.006. View

20.

Brady M, Sartiano G, Rosenblum S, Zaglama N, Bauguess C . The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol. 1987; 32(6):593-6. DOI: 10.1007/BF02455994. View